DE69835844T2 - Imidazonaphthyridine und ihre verwendung zur induzierung der biosynthese von cytokin - Google Patents

Imidazonaphthyridine und ihre verwendung zur induzierung der biosynthese von cytokin Download PDF

Info

Publication number
DE69835844T2
DE69835844T2 DE69835844T DE69835844T DE69835844T2 DE 69835844 T2 DE69835844 T2 DE 69835844T2 DE 69835844 T DE69835844 T DE 69835844T DE 69835844 T DE69835844 T DE 69835844T DE 69835844 T2 DE69835844 T2 DE 69835844T2
Authority
DE
Germany
Prior art keywords
alkyl
compound
compounds
formula
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69835844T
Other languages
German (de)
English (en)
Other versions
DE69835844D1 (de
Inventor
Kyle J. Lindstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Publication of DE69835844D1 publication Critical patent/DE69835844D1/de
Application granted granted Critical
Publication of DE69835844T2 publication Critical patent/DE69835844T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69835844T 1997-12-11 1998-12-11 Imidazonaphthyridine und ihre verwendung zur induzierung der biosynthese von cytokin Expired - Fee Related DE69835844T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6927697P 1997-12-11 1997-12-11
US69276P 1997-12-11

Publications (2)

Publication Number Publication Date
DE69835844D1 DE69835844D1 (de) 2006-10-19
DE69835844T2 true DE69835844T2 (de) 2007-04-19

Family

ID=22087889

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69826518T Expired - Fee Related DE69826518T2 (de) 1997-12-11 1998-12-11 Imidazonaphthyridinderivate und ihre verwendung zur induzierung von biosythese von cytokin
DE69835309T Expired - Lifetime DE69835309T2 (de) 1997-12-11 1998-12-11 Imidazonaphthyridinderivate und ihre verwendung zur induzierung von biosythese von cytokin
DE69835844T Expired - Fee Related DE69835844T2 (de) 1997-12-11 1998-12-11 Imidazonaphthyridine und ihre verwendung zur induzierung der biosynthese von cytokin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69826518T Expired - Fee Related DE69826518T2 (de) 1997-12-11 1998-12-11 Imidazonaphthyridinderivate und ihre verwendung zur induzierung von biosythese von cytokin
DE69835309T Expired - Lifetime DE69835309T2 (de) 1997-12-11 1998-12-11 Imidazonaphthyridinderivate und ihre verwendung zur induzierung von biosythese von cytokin

Country Status (28)

Country Link
US (14) US6194425B1 (US06894165-20050517-C00155.png)
EP (1) EP1040112B1 (US06894165-20050517-C00155.png)
JP (4) JP4283438B2 (US06894165-20050517-C00155.png)
KR (3) KR100563175B1 (US06894165-20050517-C00155.png)
CN (1) CN1154647C (US06894165-20050517-C00155.png)
AT (3) ATE277046T1 (US06894165-20050517-C00155.png)
AU (1) AU753864B2 (US06894165-20050517-C00155.png)
BR (1) BR9814275A (US06894165-20050517-C00155.png)
CA (1) CA2311456C (US06894165-20050517-C00155.png)
CZ (1) CZ307184B6 (US06894165-20050517-C00155.png)
DE (3) DE69826518T2 (US06894165-20050517-C00155.png)
DK (1) DK1512686T3 (US06894165-20050517-C00155.png)
EE (1) EE04314B1 (US06894165-20050517-C00155.png)
ES (3) ES2227902T3 (US06894165-20050517-C00155.png)
HK (1) HK1070655A1 (US06894165-20050517-C00155.png)
HR (1) HRP20000363B1 (US06894165-20050517-C00155.png)
HU (1) HUP0101155A3 (US06894165-20050517-C00155.png)
IL (4) IL136556A0 (US06894165-20050517-C00155.png)
NO (3) NO316687B1 (US06894165-20050517-C00155.png)
NZ (1) NZ504776A (US06894165-20050517-C00155.png)
PL (1) PL193915B1 (US06894165-20050517-C00155.png)
PT (3) PT1512685E (US06894165-20050517-C00155.png)
RU (3) RU2312867C2 (US06894165-20050517-C00155.png)
SI (1) SI1512686T1 (US06894165-20050517-C00155.png)
SK (2) SK286304B6 (US06894165-20050517-C00155.png)
TR (1) TR200001705T2 (US06894165-20050517-C00155.png)
UA (1) UA67760C2 (US06894165-20050517-C00155.png)
WO (1) WO1999029693A1 (US06894165-20050517-C00155.png)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
CN1555264A (zh) 1999-01-08 2004-12-15 3M 用于治疗粘膜病症的含咪喹莫特或其它免疫应答调节剂的制剂
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1438958A1 (en) * 1999-06-10 2004-07-21 3M Innovative Properties Company Carbamate substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
SI1198233T1 (sl) * 1999-06-10 2007-02-28 3M Innovative Properties Co S sulfonamidom in sulfamidom substituirani imidazokinolini
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20040209877A1 (en) * 2000-04-13 2004-10-21 Shelby Nancy J. Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans
EP1360486A2 (en) * 2000-12-08 2003-11-12 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
CA2598144A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
EP1427445A4 (en) * 2001-08-30 2006-09-06 3M Innovative Properties Co METHOD FOR MATURIZING PLASMACYTIDES DENDRITIC CELLS USING IMMUNE RESPONSE MODIFYING MOLECULES
AU2002343728A1 (en) * 2001-11-16 2003-06-10 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
WO2003045391A1 (en) * 2001-11-29 2003-06-05 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
BR0307788A (pt) * 2002-02-22 2006-04-04 3M Innovative Properties Co método de redução e tratamento de imunossupressão induzida por uv-b
US6797718B2 (en) * 2002-06-07 2004-09-28 3M Innovative Properties Company Ether substituted imidazopyridines
WO2004032829A2 (en) 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
WO2004028539A2 (en) * 2002-09-26 2004-04-08 3M Innovative Properties Company 1h-imidazo dimers
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
NZ540826A (en) 2002-12-20 2008-07-31 3M Innovative Properties Co Aryl / hetaryl substituted imidazoquinolines
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
WO2004078138A2 (en) * 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
BRPI0408125A (pt) * 2003-03-07 2006-03-01 3M Innovative Properties Co 1-amino 1h-imidazoquinolinas
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
EP1603476A4 (en) 2003-03-13 2010-01-13 3M Innovative Properties Co PROCESS FOR REMOVING TATTOO
NZ567227A (en) * 2003-03-13 2010-01-29 3M Innovative Properties Co Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2521682A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2004110992A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
BRPI0413164A (pt) * 2003-07-31 2006-10-03 3M Innovative Properties Co composições bioativas compreendendo as triazinas
WO2005016275A2 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Formulations containing an immune response modifier
JP2007502288A (ja) * 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ含有化合物
PL1653959T3 (pl) 2003-08-14 2015-10-30 3M Innovative Properties Co Modyfikatory odpowiedzi immunologicznej modyfikowane lipidami
ES2545826T3 (es) * 2003-08-14 2015-09-16 3M Innovative Properties Company Modificadores de la respuesta inmune modificados con lípidos
JP2007504145A (ja) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
CA2536249A1 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
EP1658076B1 (en) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US20060216333A1 (en) * 2003-09-02 2006-09-28 Miller Richard L Methods related to the treatment of mucosal associated conditions
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
EP1668010A2 (en) * 2003-10-01 2006-06-14 Taro Pharmaceuticals U.S.A., Inc. Method of preparing 4-amino-1h -imidazo(4,5- c )quinolines and acid addition salts thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
KR20060120069A (ko) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
JP2007509987A (ja) * 2003-10-31 2007-04-19 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物による好中球活性化
AU2004291122A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
AU2004291101A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
JP4891088B2 (ja) 2003-11-25 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー 置換されたイミダゾ環系および方法
AU2004293096A1 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
EP1694674A4 (en) * 2003-12-04 2010-07-07 3M Innovative Properties Co IMIDAZO CYCLIC ETHERS SUBSTITUTED WITH SULFONE
US7888349B2 (en) * 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
US8802853B2 (en) * 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005067500A2 (en) * 2003-12-30 2005-07-28 3M Innovative Properties Company Enhancement of immune responses
US8735421B2 (en) * 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
EP1729768B1 (en) 2004-03-15 2018-01-10 Meda AB Immune response modifier formulations and methods
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1735010A4 (en) * 2004-04-09 2008-08-27 3M Innovative Properties Co METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
MXPA06012451A (es) * 2004-04-28 2007-01-31 3M Innovative Properties Co Composiciones y metodos para vacunacion por la mucosa.
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2005123080A2 (en) * 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006028545A2 (en) * 2004-06-18 2006-03-16 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20060045886A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
EP1789042B1 (en) * 2004-09-02 2012-05-02 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
AU2005282523A1 (en) * 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
WO2006042254A2 (en) * 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines
WO2006053166A1 (en) * 2004-11-12 2006-05-18 Bristol-Myers Squibb Company 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
ATE538124T1 (de) 2004-11-12 2012-01-15 Bristol Myers Squibb Co Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
JP2008523076A (ja) * 2004-12-08 2008-07-03 スリーエム イノベイティブ プロパティズ カンパニー 免疫調節性の組成物、合剤、および方法
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
JP2008526765A (ja) * 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 皮膚転移の処置
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
WO2006083440A2 (en) 2004-12-30 2006-08-10 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
US20080188513A1 (en) * 2004-12-30 2008-08-07 Taked Pharmaceutical Company Limited 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate
EP1853594A2 (en) * 2005-01-27 2007-11-14 Alma Mater Studiorum -Universita' di Bologna Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
US8378102B2 (en) 2005-02-09 2013-02-19 3M Innovative Properties Company Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
EP1846419B1 (en) 2005-02-09 2014-04-16 3M Innovative Properties Company Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines
JP2008530113A (ja) 2005-02-11 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシラミン置換イミダゾ［４，５−ｃ］環化合物および方法
US8658666B2 (en) * 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
CA2598656A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2598695A1 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
JP2008531568A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキルで置換されたイミダゾナフチリジン
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
BRPI0608011A2 (pt) * 2005-03-14 2009-11-03 Graceway Pharmaceuticals Llc uso de uma formulação para o tratamento da queratose actìnica e uso de 2-metil-1-(2-metilpropil)-1h-imidazo[4,5-c][1,5] naftiridin-4-amina
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
EP1863770A4 (en) * 2005-04-01 2010-05-05 Coley Pharm Group Inc RING CLOSURE AND CORRESPONDING METHODS AND INTERMEDIATE PRODUCTS
WO2006116475A2 (en) 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
JP2009507795A (ja) * 2005-08-31 2009-02-26 スミスクライン ビーチャム コーポレーション 化合物
CA2621831A1 (en) * 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
AU2006311871B2 (en) 2005-11-04 2011-03-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
WO2007079086A1 (en) * 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
WO2007106854A2 (en) * 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2007106852A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
WO2007143526A2 (en) * 2006-06-05 2007-12-13 Coley Pharmaceutical Group, Inc. Substituted tetrahydroimidazonaphthyridines and methods
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
NO343857B1 (no) * 2006-07-18 2019-06-24 Meda Ab Immunresponsmodifiserende skumformuleringer
CA2659733A1 (en) * 2006-07-31 2008-02-07 3M Innovative Properties Company Sterilized topical compositions of 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine
US8178539B2 (en) * 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
EP2121023A1 (en) * 2006-12-22 2009-11-25 3M Innovative Properties Company Controlled release composition and process
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US20090018155A1 (en) 2007-02-08 2009-01-15 Gregory Jefferson J Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
DK2378876T3 (en) 2008-12-19 2019-03-11 Medicis Pharmaceutical Corp IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS
KR101730351B1 (ko) 2009-03-25 2017-04-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
WO2010114898A1 (en) * 2009-03-31 2010-10-07 Arqule, Inc. Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
US8511006B2 (en) * 2009-07-02 2013-08-20 Owens Corning Intellectual Capital, Llc Building-integrated solar-panel roof element systems
MX336923B (es) 2009-07-13 2016-02-05 Medicis Pharmaceutical Corp Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales.
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
WO2011086053A1 (en) * 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
AU2011270724B2 (en) 2010-06-25 2016-10-06 Medicis Pharmaceutical Corporation Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
SI2606047T1 (sl) 2010-08-17 2017-04-26 3M Innovative Properties Company Lipidirani sestavki spojine, ki modificira imunski odgovor, formulacije in postopki
MX355623B (es) 2011-06-03 2018-04-25 3M Innovative Properties Co Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas.
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
US9492682B2 (en) 2011-09-14 2016-11-15 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
JP6496549B2 (ja) 2011-11-30 2019-04-03 サレプタ セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症における誘発されたエクソン包含
WO2013162828A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
EP2941233B1 (en) 2013-01-07 2020-10-07 The Trustees of the University of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
EP3024476A1 (en) 2013-07-26 2016-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
JP6446054B2 (ja) 2013-11-05 2018-12-26 スリーエム・イノベイティブ・プロパティーズ・カンパニー ゴマ油ベースの注射製剤
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US9827329B2 (en) 2014-01-10 2017-11-28 Birdie Biopharmaceuticals, Inc. Compounds and compositions for immunotherapy
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
EP3298131B1 (en) 2015-05-20 2023-04-26 The Regents of The University of California Method for generating human dendritic cells for immunotherapy
CN113402518B (zh) * 2015-08-31 2023-08-22 3M创新有限公司 含有取代的胍基团的咪唑并[4,5-c]环化合物
KR102685007B1 (ko) 2015-08-31 2024-07-12 쓰리엠 이노베이티브 프로퍼티즈 컴파니 구아니딘 치환된 이미다조[4,5-c] 고리 화합물
JP6873980B2 (ja) * 2015-09-14 2021-05-19 ファイザー・インク ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
JP6883806B2 (ja) * 2016-03-09 2021-06-09 国立大学法人大阪大学 化合物、及びこれを含む有機半導体材料
DK3458475T3 (da) 2016-05-16 2022-09-12 Access To Advanced Health Inst Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
JP7010286B2 (ja) 2016-08-26 2022-01-26 スリーエム イノベイティブ プロパティズ カンパニー グアニジノ基で置換された縮合［１，２］イミダゾ［４，５－ｃ］環状化合物
BR112019004042A2 (pt) 2016-08-30 2019-05-28 Dana Farber Cancer Inst Inc composições de liberação de fármaco e usos das mesmas
AU2017356673B2 (en) 2016-11-09 2023-11-09 Pulmotect, Inc. Methods and compositions for adaptive immune modulation
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
KR20190095931A (ko) 2016-12-14 2019-08-16 프로제너티, 인크. 섭취가능한 디바이스를 사용하여 방출된 il-12/il-23 저해제로의 위장관 질환의 치료
TW201834690A (zh) 2016-12-14 2018-10-01 美商寶珍那提公司 以免疫抑制劑治療胃腸道疾病
JP2020502126A (ja) 2016-12-14 2020-01-23 プロジェニティ， インコーポレイテッド 消化管疾病のｊａｋ阻害薬による治療
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
CA3045472A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
US10766896B2 (en) 2017-03-01 2020-09-08 3M Innovative Properties Company Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups
WO2018183931A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
IL312120A (en) 2017-06-23 2024-06-01 Birdie Biopharmaceuticals Inc medical preparation
ES2951817T3 (es) 2017-08-22 2023-10-25 Dynavax Tech Corp Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos
WO2019099412A1 (en) 2017-11-14 2019-05-23 Dynavax Technologies Corporation Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
JP7251893B2 (ja) 2018-02-28 2023-04-04 スリーエム イノベイティブ プロパティズ カンパニー Ｎ－１分枝基を有する置換イミダゾ［４，５－ｃ］キノリン化合物
EP3759129A1 (en) 2018-02-28 2021-01-06 Pfizer Inc Il-15 variants and uses thereof
JP7057843B2 (ja) 2018-05-23 2022-04-20 ファイザー・インク ＧＵＣＹ２ｃに特異的な抗体及びその使用
WO2019224715A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for cd3 and uses thereof
US11884662B2 (en) 2018-05-24 2024-01-30 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
CN113166143B (zh) 2018-11-26 2024-06-04 舒万诺知识产权公司 N-1支链烷基醚取代的咪唑并[4,5-c]喹啉化合物、组合物和方法
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2020245706A1 (en) 2019-06-06 2020-12-10 3M Innovative Properties Company N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
WO2020250089A1 (en) 2019-06-12 2020-12-17 3M Innovative Properties Company Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
AU2020410410A1 (en) 2019-12-17 2022-06-09 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
JP2023533793A (ja) 2020-07-17 2023-08-04 ファイザー・インク 治療用抗体およびそれらの使用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3764681A (en) * 1970-07-08 1973-10-09 Lilly Co Eli Certain tetrazolo-(1,5-a) quinoline compounds as fungus control agents
US3917624A (en) 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
DE69108920T2 (de) 1990-10-05 1995-11-30 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Verfahren zur herstellung von imidazo[4,5-c]chinolin-4-aminen.
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5378698A (en) * 1991-10-21 1995-01-03 Shionogi & Co., Ltd. Benzothiazepine derivatives
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
ES2149276T3 (es) 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5585612A (en) 1995-03-20 1996-12-17 Harp Enterprises, Inc. Method and apparatus for voting
JPH09208584A (ja) 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
JPH09255926A (ja) 1996-03-26 1997-09-30 Diatex Co Ltd 粘着テープ
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
CZ294563B6 (cs) 1996-10-25 2005-02-16 Minnesota Mining And Manufacturing Company Sloučeniny představující modifikátory imunitní odezvy při léčení nemocí mediovaných TH2 buňkami a nemocí odvozených
DE69715769T2 (de) * 1996-11-04 2003-05-28 Bayer Cropscience S.A., Lyon 1-Polyarylpyrazole als Pestizide
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6069149A (en) 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
JPH11222432A (ja) 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
JPH11255926A (ja) 1998-03-13 1999-09-21 Toray Ind Inc シリコーン成型品およびその製造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CN1555264A (zh) 1999-01-08 2004-12-15 3M 用于治疗粘膜病症的含咪喹莫特或其它免疫应答调节剂的制剂
US6545485B1 (en) * 1999-01-21 2003-04-08 Radar Engineers Ultrasonic pinpointer for power system sources of interference
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (ja) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6660260B1 (en) * 1999-09-21 2003-12-09 Mayo Foundation For Medical Education And Research Bioprosthetic heart valves
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (ja) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
EP1360486A2 (en) * 2000-12-08 2003-11-12 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
CA2449754A1 (en) 2001-06-15 2002-12-27 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
EP1427445A4 (en) * 2001-08-30 2006-09-06 3M Innovative Properties Co METHOD FOR MATURIZING PLASMACYTIDES DENDRITIC CELLS USING IMMUNE RESPONSE MODIFYING MOLECULES
US6667347B2 (en) * 2001-09-14 2003-12-23 Chevron U.S.A. Inc. Scrubbing CO2 from methane-containing gases using an aqueous stream
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
AU2002343728A1 (en) * 2001-11-16 2003-06-10 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
WO2003045391A1 (en) * 2001-11-29 2003-06-05 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
BR0307788A (pt) * 2002-02-22 2006-04-04 3M Innovative Properties Co método de redução e tratamento de imunossupressão induzida por uv-b
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
JP2005531599A (ja) * 2002-05-29 2005-10-20 スリーエム イノベイティブ プロパティズ カンパニー イミダゾ［４，５−ｃ］ピリジン−４−アミンのための方法
US6797718B2 (en) * 2002-06-07 2004-09-28 3M Innovative Properties Company Ether substituted imidazopyridines
WO2004032829A2 (en) * 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
WO2004028539A2 (en) * 2002-09-26 2004-04-08 3M Innovative Properties Company 1h-imidazo dimers
EP1572236A4 (en) * 2002-11-14 2007-01-03 Pintex Pharmaceuticals Inc PINE RATE1 IN HEALTHY FABRIC AND IN CANCER FABRIC
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
NZ540826A (en) * 2002-12-20 2008-07-31 3M Innovative Properties Co Aryl / hetaryl substituted imidazoquinolines
AU2003300184B8 (en) * 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
WO2004078138A2 (en) * 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
BRPI0408125A (pt) * 2003-03-07 2006-03-01 3M Innovative Properties Co 1-amino 1h-imidazoquinolinas
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
EP1603476A4 (en) * 2003-03-13 2010-01-13 3M Innovative Properties Co PROCESS FOR REMOVING TATTOO
NZ567227A (en) * 2003-03-13 2010-01-29 3M Innovative Properties Co Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
WO2004087049A2 (en) * 2003-03-25 2004-10-14 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
CA2521682A1 (en) 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
BRPI0414045A (pt) * 2003-09-05 2006-10-24 Anadys Pharmaceuticals Inc administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c
US20080188513A1 (en) * 2004-12-30 2008-08-07 Taked Pharmaceutical Company Limited 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate

Also Published As

Publication number Publication date
IL178092A (en) 2007-10-31
IL136556A (en) 2007-03-08
JP2008115190A (ja) 2008-05-22
NO20002663L (no) 2000-08-11
US6894165B2 (en) 2005-05-17
KR100563175B1 (ko) 2006-03-27
US7678918B2 (en) 2010-03-16
US20080091010A1 (en) 2008-04-17
ES2273138T3 (es) 2007-05-01
US7038051B2 (en) 2006-05-02
RU2312867C2 (ru) 2007-12-20
KR20040011533A (ko) 2004-02-05
SK285872B6 (sk) 2007-10-04
DE69835309D1 (de) 2006-08-31
CA2311456A1 (en) 1999-06-17
NO20035718L (no) 2000-08-11
NZ504776A (en) 2002-07-26
US6638944B2 (en) 2003-10-28
SK286304B6 (en) 2008-07-07
UA67760C2 (uk) 2004-07-15
KR20040011532A (ko) 2004-02-05
NO20035718D0 (no) 2003-12-19
US20050288320A1 (en) 2005-12-29
RU2003126259A (ru) 2005-02-27
DE69835309T2 (de) 2007-07-19
NO328045B1 (no) 2009-11-16
EP1040112B1 (en) 2004-09-22
HUP0101155A2 (hu) 2001-12-28
DE69826518T2 (de) 2005-09-22
IL136556A0 (en) 2001-06-14
JP4203067B2 (ja) 2008-12-24
ES2227902T3 (es) 2005-04-01
US20040006098A1 (en) 2004-01-08
US20020173654A1 (en) 2002-11-21
US6514985B1 (en) 2003-02-04
SI1512686T1 (sl) 2007-02-28
DE69835844D1 (de) 2006-10-19
ATE333456T1 (de) 2006-08-15
DK1512686T3 (da) 2007-01-15
JP2006083188A (ja) 2006-03-30
WO1999029693A8 (en) 2004-11-04
CZ2007268A3 (cs) 2016-09-29
PT1040112E (pt) 2005-01-31
EE200000349A (et) 2001-10-15
US6693113B2 (en) 2004-02-17
US6194425B1 (en) 2001-02-27
CN1284957A (zh) 2001-02-21
CA2311456C (en) 2010-11-02
US6699878B2 (en) 2004-03-02
PT1512686E (pt) 2007-01-31
US20050107421A1 (en) 2005-05-19
CZ307184B6 (cs) 2018-02-28
US6949646B2 (en) 2005-09-27
PT1512685E (pt) 2006-12-29
IL178091A (en) 2007-10-31
ATE338757T1 (de) 2006-09-15
CN1154647C (zh) 2004-06-23
TR200001705T2 (tr) 2001-07-23
RU2314307C2 (ru) 2008-01-10
NO316687B1 (no) 2004-04-05
RU2003126258A (ru) 2005-03-10
NO20035719D0 (no) 2003-12-19
US6797716B2 (en) 2004-09-28
NO20002663D0 (no) 2000-05-24
US20060128674A1 (en) 2006-06-15
ES2270249T3 (es) 2007-04-01
EE04314B1 (et) 2004-06-15
PL193915B1 (pl) 2007-03-30
KR100642703B1 (ko) 2006-11-10
US6747040B2 (en) 2004-06-08
WO1999029693A1 (en) 1999-06-17
US20040204436A1 (en) 2004-10-14
US6624172B2 (en) 2003-09-23
HRP20000363A2 (en) 2001-06-30
JP4283438B2 (ja) 2009-06-24
HK1070655A1 (en) 2005-06-24
HRP20000363B1 (en) 2005-06-30
AU753864B2 (en) 2002-10-31
JP2007262093A (ja) 2007-10-11
DE69826518D1 (de) 2004-10-28
US20070167481A1 (en) 2007-07-19
US20030083500A1 (en) 2003-05-01
SK8352000A3 (en) 2001-03-12
HUP0101155A3 (en) 2002-10-28
AU1912399A (en) 1999-06-28
US20030212093A1 (en) 2003-11-13
US20040023932A1 (en) 2004-02-05
KR100642702B1 (ko) 2006-11-10
EP1040112A1 (en) 2000-10-04
BR9814275A (pt) 2000-10-03
ATE277046T1 (de) 2004-10-15
US7335773B2 (en) 2008-02-26
JP2001525411A (ja) 2001-12-11
KR20010033016A (ko) 2001-04-25
PL341159A1 (en) 2001-03-26
US20030096998A1 (en) 2003-05-22
RU2221798C2 (ru) 2004-01-20

Similar Documents

Publication Publication Date Title
DE69835844T2 (de) Imidazonaphthyridine und ihre verwendung zur induzierung der biosynthese von cytokin
DE60117859T2 (de) HARNSTOFFSUBSTITUIERTE IMIDAZOCHINOLINETHER und Arzneimittel, die diese umfassen.
DE60030293T2 (de) Harnstoffsubstituierte imidazochinoline
DE69930327T2 (de) Oxazolo-, Thiazolo- und Selenazolo-Ä4,5-cÜnaphthyridin-4-amine und Analoge davon
DE60030126T2 (de) Sulfonamid- und sulfamid-substituierte imidazochinoline
DE60029956T2 (de) Amid-substituierte Imidazochinoline
US6573273B1 (en) Urea substituted imidazoquinolines
US6660735B2 (en) Urea substituted imidazoquinoline ethers
US6518280B2 (en) Imidazonaphthyridines
US20020107262A1 (en) Substituted imidazopyridines
DE60001138T2 (de) Polycyclische Azaindolderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
EP1512686B1 (en) Imidazonaphthyridines and their use in inducing cytokine biosynthesis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP

8339 Ceased/non-payment of the annual fee